KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/38826

Title:	KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Authors:	HARRINGTON, Kevin Joseph; RISCHIN, Danny; GREIL, Richard; SOULIERES, Denis; TAHARA, Makoto; CASTRO, Gilberto; PSYRRI, Amanda; BASTE, Neus; NEUPANE, Prakash C.; BRATLAND, Ase; FUEREDER, Thorsten; HUGHES, Brett Gordon Maxwell; MESIA, Ricard; NGAMPHAIBOON, Nuttapong; RORDORF, Tamara; ISHAK, Wan Zamaniah Wan; ZHANG, Yayan; GUMUSCU, Burak; SWABY, Ramona F.; BURTNESS, Barbara
Citation:	JOURNAL OF CLINICAL ONCOLOGY, v.38, n.15, suppl.S, 2020
Appears in Collections:	Comunicações em Eventos - FM/MDR Departamento de Radiologia - FM/MDR Comunicações em Eventos - HC/ICESP Instituto do Câncer do Estado de São Paulo - HC/ICESP Comunicações em Eventos - LIM/24 LIM/24 - Laboratório de Oncologia Experimental

Files in This Item:

There are no files associated with this item.